Prague welcomed nearly 200 researchers from MIT, Harvard, Stanford, and other leading institutions for the Prague Metabolism and Signaling Symposium, focused on cellular metabolism, aging, and cancer.

Scientists at IOCB Prague developed a breakthrough technology that accelerates aptamer discovery, opening new opportunities for diagnostics, therapeutics, and wearable biosensors.

Researchers at IOCB Prague developed deoxyribozyme-based sensors that detect DNA-editing enzymes faster and cheaper, while machine learning helps design new catalytic DNA tools.

The IOCB Tech Foundation has become the IOCB Foundation. With stronger ties to IOCB Prague, it aims to accelerate technology transfer, support innovation, and expand science philanthropy.

IOCB Prague hosted HIV prevention pioneers discussing lenacapavir, a long-acting drug that could shift HIV prevention from daily pills to a single yearly injection.

New androstane-based steroid derivatives can significantly improve antibiotic efficacy against multidrug-resistant Staphylococcus aureus, offering a promising strategy to overcome efflux-mediated resistance.

MROA enables sensitive conformational analysis of both chiral and achiral molecules, opening new possibilities for molecular studies in liquid systems.

IOCB Prague researchers developed potent CD73 inhibitors that restore T cell activity and reduce adenosine, opening new paths for cancer immunotherapy.

IOCB Prague researchers developed a membrane-mimicking screening platform that identified selective rhomboid protease inhibitors with potential for Parkinson’s disease and bacterial infections.

Scientists at IOCB Prague reveal a previously unknown mechanism that initiates gene transcription. Using cryo-EM, they uncover how alarmone molecules enable RNA synthesis under stress.